cerebral dopamine neurotrophic factor

From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

Home
Ligands
cerebral dopamine neurotrophic factor (Human)

GtoPdb Ligand ID: 13048

Synonyms: arginine-rich, mutated in early stage tumors-like 1 | ARMETL1

Compound class: Endogenous peptide in human, mouse or rat

Comment: CDNF is a dopamine neuron neurotropic factor [5]. It provides cytoprotective effects in neurodegenerative disease models by reducing the activating effect of endoplasmic reticulum stress on the unfolded protein response (UPR) pathway [4,7]. Specifically, CDNF has been shown to protect dopamine neurons and improve motor function in animal Parkinson's disease models [1-2,5-6,8]. However therapeutic use of proteins like CDNF is invasive (intracranial administration) and requires clinical expertise.

Species: Human

References
1. Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, Lindholm P, Lindahl M, Tuominen RK, Saarma M, Hoffer B et al.. (2012) CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant, 21 (6): 1213-23. [PMID:21943517]
2. Er S, Airavaara M. (2023) Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease. Biochem Soc Trans, 51 (1): 245-257. [PMID:36794783]
3. Huttunen HJ, Booms S, Sjögren M, Kerstens V, Johansson J, Holmnäs R, Koskinen J, Kulesskaya N, Fazio P, Woolley M et al.. (2023) Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial. Mov Disord, 38 (7): 1209-1222. [PMID:37212361]
4. Lindholm P, Saarma M. (2022) Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism. Mol Psychiatry, 27 (3): 1310-1321. [PMID:34907395]
5. Lindholm P, Voutilainen MH, Laurén J, Peränen J, Leppänen VM, Andressoo JO, Lindahl M, Janhunen S, Kalkkinen N, Timmusk T et al.. (2007) Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature, 448 (7149): 73-7. [PMID:17611540]
6. Pakarinen E, Lindholm P. (2023) CDNF and MANF in the brain dopamine system and their potential as treatment for Parkinson's disease. Front Psychiatry, 14: 1188697. [PMID:37555005]
7. van Ziel AM, Scheper W. (2020) The UPR in Neurodegenerative Disease: Not Just an Inside Job. Biomolecules, 10 (8): 1090. [PMID:32707908]
8. Voutilainen MH, Bäck S, Peränen J, Lindholm P, Raasmaja A, Männistö PT, Saarma M, Tuominen RK. (2011) Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp Neurol, 228 (1): 99-108. [PMID:21185834]

References

1. Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, Lindholm P, Lindahl M, Tuominen RK, Saarma M, Hoffer B et al.. (2012)
CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice.
Cell Transplant, 21 (6): 1213-23. [PMID:21943517]

2. Er S, Airavaara M. (2023)
Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease.
Biochem Soc Trans, 51 (1): 245-257. [PMID:36794783]

3. Huttunen HJ, Booms S, Sjögren M, Kerstens V, Johansson J, Holmnäs R, Koskinen J, Kulesskaya N, Fazio P, Woolley M et al.. (2023)
Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial.
Mov Disord, 38 (7): 1209-1222. [PMID:37212361]

4. Lindholm P, Saarma M. (2022)
Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism.
Mol Psychiatry, 27 (3): 1310-1321. [PMID:34907395]

5. Lindholm P, Voutilainen MH, Laurén J, Peränen J, Leppänen VM, Andressoo JO, Lindahl M, Janhunen S, Kalkkinen N, Timmusk T et al.. (2007)
Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.
Nature, 448 (7149): 73-7. [PMID:17611540]

6. Pakarinen E, Lindholm P. (2023)
CDNF and MANF in the brain dopamine system and their potential as treatment for Parkinson's disease.
Front Psychiatry, 14: 1188697. [PMID:37555005]

7. van Ziel AM, Scheper W. (2020)
The UPR in Neurodegenerative Disease: Not Just an Inside Job.
Biomolecules, 10 (8): 1090. [PMID:32707908]

8. Voutilainen MH, Bäck S, Peränen J, Lindholm P, Raasmaja A, Männistö PT, Saarma M, Tuominen RK. (2011)
Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.
Exp Neurol, 228 (1): 99-108. [PMID:21185834]